Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN. Effects of AMR101, a pure ethyl eicosapentaenoic acid omega-3 fatty acid, on lipoprotein particle concentration and size in patients with very high triglycerides (the MARINE study) [abstract]. Circulation. 2011;124:A14232.
Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. AMR101 lowers triglycerides, atherogenic lipoprotein, phospholipase A2, and high-sensitivity C- reactive protein levels in patients with high triglycerides and on background statin therapy (the ANCHOR study) [abstract]. Circulation. 2011;124:A15071.
Mason RP, Jacob RF. Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism. Biochim Biophys Acta. 2015;1848:502-509.
Free:
http://dx.doi.org/10.1016/j.bbamem.2014.10.016
Braeckman RA, Stirtan WG, Soni PN. Effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) on pharmacokinetic parameters of rosiglitazone in healthy subjects. Clin Pharmacol Drug Dev. 2014 [Epub ahead of print].
Free:
http://onlinelibrary.wiley.com/doi/10.1002/cpdd.150/pdf
Braeckman RA, Manku MS, Ballantyne CM, Stirtan WG, Soni PN. Effects of AMR101, a pure eicosapentaenoic omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study) [abstract]. Circulation. 2012;126:A18549.
Bays H, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. High-sensitivity C-reactive protein effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) with and without stable statin therapy in hypertriglyceridemic patients with metabolic syndrome [abstract]. Circulation. 2013;128:A19342.
Ballantyne CM, Bays HE, Braeckman RA, Philip S, Stirtan WG, Doyle RT Jr, Soni PN, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies [abstract]. Circulation. 2014;130:A16803.
Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN. Effects of AMR101 on lipid and inflammatory parameters in patients with diabetes mellitus-2 and residual elevated triglycerides (200-500 mg/dL) on statin therapy at LDL-C goal: the ANCHOR study [abstract 629-P]. Diabetes. 2012;61(suppl 1):A159-A160.
Braeckman RA, Stirtan WG, Soni PN. Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin. Clin Drug Investig. 2015 Jan;35(1):45-51.
http://link.springer.com/article/10.1007/s40261-014-0252-8
